#United States #Carlsbad #ImpediMed #Medical Technologies #Erik Anderson

ImpediMed Appoints Erik Anderson as Board Member

ImpediMed, a pioneer in the medical technology sector, has made a significant decision by appointing Erik Anderson to its Board of Directors. This strategic move is aimed at driving the growth and commercialization of medical technologies centered around fluid and body composition management.

A Wealth of Experience

Erik Anderson brings over 16 years of experience in hospital sales and health system account management to his new role. His extensive background includes commercializing innovative clinical technologies with a focus on breast health, body composition, and medical aesthetics. This expertise aligns perfectly with ImpediMed's key initiatives, especially in addressing breast cancer-related lymphedema (BCRL) and enhancing heart health through its cutting-edge products.

Prior to joining ImpediMed, Anderson served as the division president of Hologic's Breast and Skeletal Health Division. Under his leadership, this major division, responsible for a global revenue exceeding $1.6 billion, thrived. His work fostered deep connections within oncology and the breast cancer survivorship landscape, crucial elements where ImpediMed's BCRL solution is utilized. His experience with Hologic’s Skeletal Health portfolio, involving Dual-Energy X-ray Absorptiometry (DXA) for body composition measurement, places him in a prime position to impact ImpediMed's growth trajectory.

Growth and Commercialization Focus

The appointment reflects ImpediMed's ongoing commitment to invest in the burgeoning cancer survivorship market. Christine Emmanuel-Donnelly, the Board Chair, expressed enthusiasm regarding Anderson's addition, highlighting the immense potential of the BCRL application within ImpediMed's digital platform. Emmanuel-Donnelly noted that Anderson's deep understanding of the U.S. hospital system will play a vital role as the company continues its push towards successful commercialization efforts across BCRL and expands its focus on heart health and overall body composition.

Future Vision

In his own words, Anderson stated, "I am passionate about ImpediMed and the role SOZO plays in the breast cancer survivorship pathway. I see enormous growth potential, especially in areas of survivorship care, heart health, and body composition management." His optimistic outlook aligns with ImpediMed's vision of leveraging technology to enhance patient care and outcomes.

About ImpediMed

ImpediMed stands at the forefront of medical technology innovation. The company specializes in bioimpedance spectroscopy (BIS) devices, enabling clinicians to gain real-time insights for tailored patient management. Known for its SOZO® Digital Health Platform, ImpediMed offers FDA-cleared BIS technology that measures fluid status and tissue composition noninvasively. Their work centers around managing secondary lymphedema, primarily focusing on breast cancer-related conditions. Moreover, their system supports structured cancer survivorship programs and medical weight management initiatives, providing vital insights into overall health. As a trusted partner to healthcare organizations and research institutions globally, ImpediMed is redefining patient care pathways through innovative monitoring solutions.

For more details, visit ImpediMed.